CN102406927A - Method for producing human diploid cell encephalitis B inactivated vaccine - Google Patents
Method for producing human diploid cell encephalitis B inactivated vaccine Download PDFInfo
- Publication number
- CN102406927A CN102406927A CN2011103591461A CN201110359146A CN102406927A CN 102406927 A CN102406927 A CN 102406927A CN 2011103591461 A CN2011103591461 A CN 2011103591461A CN 201110359146 A CN201110359146 A CN 201110359146A CN 102406927 A CN102406927 A CN 102406927A
- Authority
- CN
- China
- Prior art keywords
- virus
- human diploid
- bioreactor
- diploid cell
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to the technical field of biology, in particular to a method for producing a human diploid cell encephalitis B inactivated vaccine. The method sequentially comprises the following steps of: resuscitating and subculturing a human diploid cell strain; culturing the human diploid cell strain by using a multi-stage bioreactor; inoculating an encephalitis B virus strain, and performing virus multiplication culture; harvesting a virus culture solution; and inactivating the virus culture solution, performing ultrafiltration, purifying, adding a glycoprotein protective agent, and preparing the vaccine. Human diploid cells are used as a cell matrix, so that the vaccine is safe and is free from exogenous factor pollution; the human diploid cells are cultured by the bioreactor through stage-by-stage linear amplification, so that the large-scale production of the vaccine with low cost, high quality, safety and stability is easy to implement; and the titer of the virus harvested solution is subjected to sampling inspection every day, so that the high expression of the harvested virus culture is ensured, and production quality is ensured.
Description
Technical field
The present invention relates to biological technical field, especially a kind of production method of Inactivated Japanese Encephalitis Vaccine.
Background technology
Encephalitis B mainly is to bite propagation by Culex tritaeniorhynchus; Virus gets in the human body through mosquito bite and at first duplicates in local organization and lymph node; Diffuse to other positions and further duplicate back generation viremia; Virus is through blood-cerebrospinal fluid barrier under the situation of or some brain tissue impairment low at immunity of organisms, invades the central nervous system and encephalitis takes place.In case morbidity, this sick case fatality rate is higher with the ratio of the back sequela that heals.At present, preventative vaccination is this sick effective means of control.
At present, on the market extensive use mainly contain Mus brain purification inactivated vaccine, hamster kidney cell inactivated vaccine, Japanese Encephalitis Vaccine,Live and four kinds of vaccines of Vero cell inactivated vaccine.Mus brain purification inactivated vaccine be with get behind the virus inoculation infecting mouse its cerebral tissue through homogenate, clarification, removal foreign protein, concentrate and deactivation is prepared from; Curative effect is comparatively definite; But because the residual and issues of purification of cerebral tissue, its large-scale production is difficult and cost is too high.Also have the property albumen in Mus source in hamster kidney cell deactivation and the attenuated live vaccine vaccine production process and produce in be prone to reason such as pollution.Though and Vero cell Japanese encephalitis inactivated vaccine is than the residue problem that is prone to realize large-scale production but has DNA.
Summary of the invention
The objective of the invention is to solve the deficiency of prior art, a kind of production method of human diploid cell Inactivated Japanese Encephalitis Vaccine is provided.
For achieving the above object, the present invention has taked following technical scheme:
A kind of production method of human diploid cell Inactivated Japanese Encephalitis Vaccine may further comprise the steps successively:
Step 1: the recovery of human diploid cell strain and the cultivation of going down to posterity: the human diploid cell strain through recovery, rolling bottle go down to posterity cultivated for 2～3 generations after, peptic cell also prepares cell suspension;
Step 2: the multi-stage biological reaction vessel of human diploid cell strain is cultivated; The bioreactor Linear magnifying technology in high that the human diploid cell suspension that will after recovery, go down to posterity cultivation and digestion, process carries out more than the secondary is cultivated;
Step 3: inoculation encephalitis b virus strain, carry out virus multiplication and cultivate: the cell density in the final bioreactor that the bioreactor Linear magnifying technology in high is cultivated reaches 10
6After individual/ml is above, cell growth medium is replaced by virus keeps liquid, and the encephalitis b virus strain is seeded to wherein, carry out virus multiplication and cultivate;
Step 4: results virus-culturing fluid: change virus and keep liquid after 24 hours, the results virus-culturing fluid, simultaneously every day the sampling Detection virus-culturing fluid titre, every batch culture fluid results 15～25 days;
Step 5: the virus-culturing fluid of results is prepared vaccine after deactivation, ultrafiltration, purification and interpolation protective agent.
Further technical scheme is, described human diploid cell strain is WI-38, MRC-5, and 2BS, any among the KMB17, described encephalitis b virus strain are P3 strain or SA14-14-2 strain.
Further technical scheme is that described bioreactor is that stirring type bioreactor or swing gas-liquid replace culture bioreactors.
Further technical scheme is, said virus is kept liquid and kept liquid for BME virus, and said protective agent is the glycoprotein protective agent.
Further technical scheme is, the human diploid cell strain in the bioreactor of each of said step 2 grade reaches 10
6Behind the cell density more than individual/ml, digestion, eluting, centrifugation is collected and re-suspended cell, and is seeded to the next stage bioreactor culture according to magnification ratio through airtight pipe-line system.
Further technical scheme is, adds microcarrier and the cell suspension that supplies cell to attach in each of said step 2 grade bioreactor, and the concentration of cell suspension that adds in the said one-level bioreactor is 10
6Individual/more than the ml, the about 10L of the working volume of said one-level bioreactor culture, described magnification ratio are 10～20 times of previous stage bioreactor working volume.
Further technical scheme is, the microcarrier that adds in described each grade bioreactor is that graininess solid microsphere carrier, porous are microsphere supported, in reticular fiber structure carrier and the sheet-like fiber structure carrier any.
Further technical scheme is, the mode of said step 4 results virus-culturing fluid is compartment results culture fluid or continous pouring formula results culture fluid.
Further technical scheme is, described compartment results culture fluid is specially: behind the virus-culturing fluid of 24～48 hours results volume of culture 80%～90%, continue to add BME and keep liquid to former volume of culture at interval.
Further technical scheme is, described continous pouring formula results culture fluid is specially: flow out virus-culturing fluid every day continuously, and every day harvesting work volume 80%～90% virus-culturing fluid, equivalent is added BME and is kept liquid continuously simultaneously.
Compared with prior art, the present invention has following beneficial effect:
(1) the present invention adopts human diploid cell as cellular matrix, safety and do not have exogenous factor and pollute.
(2) the present invention adopts the bioreactor culture of linear amplification step by step, is easy to realize lower cost, the vaccine large-scale production of better quality safety and stability.
(3) every day of the present invention sampling Detection virus results liquid the high expressed of the titre viral cultures that guaranteed to be gathered in the crops, guaranteed the quality of production.
The specific embodiment
Embodiment 1
A kind of production method of human diploid cell Inactivated Japanese Encephalitis Vaccine may further comprise the steps successively:
Step 1: the recovery of human diploid cell strain WI-38 and the cultivation of going down to posterity: human diploid cell strain WI-38 through recovery, rolling bottle go down to posterity cultivated for 2 generations after, peptic cell also prepares cell suspension;
Step 2: the multi-stage biological reaction vessel of human diploid cell strain WI-38 is cultivated; The human diploid cell WI-38 suspension that to after recovery, go down to posterity cultivation and digestion, process carries out the bioreactor Linear magnifying technology in high of secondary and cultivates;
Step 3: inoculation encephalitis b virus strain P3, carry out virus multiplication and cultivate: the cell density in the final bioreactor that the bioreactor Linear magnifying technology in high is cultivated reaches 10
6Behind individual/ml, human diploid cell WI-38 growth-promoting media is replaced by BME virus keeps liquid, and encephalitis b virus strain P3 is seeded to wherein, carry out virus multiplication and cultivate;
Step 4: results virus-culturing fluid: change BME virus and keep liquid after 24 hours, the results virus-culturing fluid, simultaneously every day the sampling Detection virus-culturing fluid titre, every batch culture fluid results 15 days;
Step 5: the virus-culturing fluid of results is prepared vaccine after deactivation, ultrafiltration, purification and interpolation glycoprotein protective agent.
Further technical scheme is that described bioreactor is a stirring type bioreactor.
Further technical scheme is, the human diploid cell strain WI-38 in the bioreactor of each of said step 2 grade reaches 10
6Behind the cell density of individual/ml, digestion, eluting, centrifugation is collected and re-suspended cell, and is seeded to the next stage bioreactor culture according to magnification ratio through airtight pipe-line system.
Further technical scheme is; Add graininess solid microsphere carrier and the human diploid cell WI-38 suspension that supplies cell to attach in each of said step 2 grade bioreactor, the human diploid cell WI-38 suspension concentration that adds in the said one-level bioreactor is 10
6Individual/ml, the about 10L of the working volume of said one-level bioreactor culture, described magnification ratio are 10 times of previous stage bioreactor working volume.
Further technical scheme is, the mode of said step 4 results virus-culturing fluid is compartment results culture fluid, is specially: behind the virus-culturing fluid of 24 hours results volume of culture 80%, continue to add BME and keep liquid to former volume of culture at interval.
Embodiment 2
A kind of production method of human diploid cell Inactivated Japanese Encephalitis Vaccine may further comprise the steps successively:
Step 1: the recovery of human diploid cell strain MRC-5 and the cultivation of going down to posterity: human diploid cell strain MRC-5 through recovery, rolling bottle go down to posterity cultivated for 3 generations after, peptic cell also prepares cell suspension;
Step 2: the multi-stage biological reaction vessel of human diploid cell strain MRC-5 is cultivated; The human diploid cell MRC-5 suspension that to after recovery, go down to posterity cultivation and digestion, process carries out three grades bioreactor Linear magnifying technology in high cultivation;
Step 3: inoculation encephalitis b virus strain P3, carry out virus multiplication and cultivate: the human diploid cell MRC-5 density in the final bioreactor that the bioreactor Linear magnifying technology in high is cultivated reaches 10
7Behind individual/ml, human diploid cell MRC-5 growth-promoting media is replaced by BME virus keeps liquid, and encephalitis b virus strain P3 is seeded to wherein, carry out virus multiplication and cultivate;
Step 4: results virus-culturing fluid: change BME virus and keep liquid after 24 hours, the results virus-culturing fluid, simultaneously every day the sampling Detection virus-culturing fluid titre, every batch culture fluid results 25 days;
Step 5: the virus-culturing fluid of results is prepared vaccine after deactivation, ultrafiltration, purification and interpolation glycoprotein protective agent.
Further technical scheme is that described bioreactor is a stirring type bioreactor.
Further technical scheme is, the human diploid cell strain MRC-5 in the bioreactor of each of said step 2 grade reaches 10
7Behind the cell density of individual/ml, digestion, eluting, centrifugation is collected and re-suspended cell, and is seeded to the next stage bioreactor culture according to magnification ratio through airtight pipe-line system.
Further technical scheme is, adds the microsphere supported and human diploid cell MRC-5 suspension of the porous that supplies cell to attach in each of said step 2 grade bioreactor, and the human diploid cell MRC-5 suspension concentration that adds in the said one-level bioreactor is 10
6Individual/ml, the about 10L of the working volume of said one-level bioreactor culture, described magnification ratio are 20 times of previous stage bioreactor working volume.
Further technical scheme is, the mode of said step 4 results virus-culturing fluid is compartment results culture fluid, is specially: behind the virus-culturing fluid of 48 hours results volume of culture 90%, continue to add BME and keep liquid to former volume of culture at interval.
Embodiment 3
A kind of production method of human diploid cell Inactivated Japanese Encephalitis Vaccine may further comprise the steps successively:
Step 1: the recovery of human diploid cell strain 2BS and the cultivation of going down to posterity: human diploid cell strain 2BS through recovery, rolling bottle go down to posterity cultivated for 2 generations after, peptic cell also prepares cell suspension;
Step 2: the multi-stage biological reaction vessel of human diploid cell strain 2BS is cultivated; The human diploid cell 2BS suspension that to after recovery, go down to posterity cultivation and digestion, process carries out the bioreactor Linear magnifying technology in high of secondary and cultivates;
Step 3: inoculation encephalitis b virus strain SA14-14-2, carry out virus multiplication and cultivate: the human diploid cell 2BS density in the final bioreactor that the bioreactor Linear magnifying technology in high is cultivated reaches 10
6Behind individual/ml, human diploid cell 2BS growth-promoting media is replaced by BME virus keeps liquid, and encephalitis b virus strain SA14-14-2 is seeded to wherein, carry out virus multiplication and cultivate;
Step 4: results virus-culturing fluid: change BME virus and keep liquid after 24 hours, the results virus-culturing fluid, simultaneously every day the sampling Detection virus-culturing fluid titre, every batch culture fluid results 15 days;
Step 5: the virus-culturing fluid of results is prepared vaccine after deactivation, ultrafiltration, purification and interpolation glycoprotein protective agent.
Further technical scheme is that described bioreactor is that swing gas-liquid replaces culture bioreactors.
Further technical scheme is, the human diploid cell strain 2BS in the bioreactor of each of said step 2 grade reaches 10
6Behind the cell density of individual/ml, digestion, eluting, centrifugation is collected and re-suspended cell, and is seeded to the next stage bioreactor culture according to magnification ratio through airtight pipe-line system.
Further technical scheme is, adds sheet-like fiber structure carrier and the human diploid cell 2BS suspension that supplies cell to attach in each of said step 2 grade bioreactor, and the human diploid cell 2BS suspension concentration that adds in the said one-level bioreactor is 10
6Individual/ml, the about 10L of the working volume of said one-level bioreactor culture, described magnification ratio are 10 times of previous stage bioreactor working volume.
Further technical scheme is; The mode of said step 4 results virus-culturing fluid is continous pouring formula results culture fluid; Be specially: flow out virus-culturing fluid every day continuously, and every day harvesting work volume 80% virus-culturing fluid, equivalent is added BME and is kept liquid continuously simultaneously.
Embodiment 4
A kind of production method of human diploid cell Inactivated Japanese Encephalitis Vaccine may further comprise the steps successively:
Step 1: the recovery of human diploid cell strain KMB17 and the cultivation of going down to posterity: human diploid cell strain KMB17 through recovery, rolling bottle go down to posterity cultivated for 3 generations after, peptic cell also prepares cell suspension;
Step 2: the multi-stage biological reaction vessel of human diploid cell strain KMB17 is cultivated; The human diploid cell KMB17 suspension that to after recovery, go down to posterity cultivation and digestion, process carries out three grades bioreactor Linear magnifying technology in high cultivation;
Step 3: inoculation encephalitis b virus strain SA14-14-2, carry out virus multiplication and cultivate: the human diploid cell KMB17 density in the final bioreactor that the bioreactor Linear magnifying technology in high is cultivated reaches 10
8Behind individual/ml, human diploid cell KMB17 growth-promoting media is replaced by BME virus keeps liquid, and encephalitis b virus strain SA14-14-2 is seeded to wherein, carry out virus multiplication and cultivate;
Step 4: results virus-culturing fluid: change BME virus and keep liquid after 24 hours, the results virus-culturing fluid, simultaneously every day the sampling Detection virus-culturing fluid titre, every batch culture fluid results 25 days;
Step 5: the virus-culturing fluid of results is prepared vaccine after deactivation, ultrafiltration, purification and interpolation glycoprotein protective agent.
Further technical scheme is that described bioreactor is that swing gas-liquid replaces culture bioreactors.
Further technical scheme is, the human diploid cell strain KMB17 in the bioreactor of each of said step 2 grade reaches 10
8Behind the cell density of individual/ml, digestion, eluting, centrifugation is collected and re-suspended cell, and is seeded to the next stage bioreactor culture according to magnification ratio through airtight pipe-line system.
Further technical scheme is; Add reticular fiber structure carrier and the human diploid cell KMB17 suspension that supplies cell to attach in each of said step 2 grade bioreactor, the human diploid cell KMB17 suspension concentration that adds in the said one-level bioreactor is 10
8Individual/ml, the about 10L of the working volume of said one-level bioreactor culture, described magnification ratio are 20 times of previous stage bioreactor working volume.
Further technical scheme is; The mode of said step 4 results virus-culturing fluid is continous pouring formula results culture fluid; Be specially: flow out virus-culturing fluid every day continuously, and every day harvesting work volume 90% virus-culturing fluid, equivalent is added BME and is kept liquid continuously simultaneously.
Claims (10)
1. the production method of a human diploid cell Inactivated Japanese Encephalitis Vaccine is characterized in that: may further comprise the steps successively:
Step 1: the recovery of human diploid cell strain and the cultivation of going down to posterity: the human diploid cell strain through recovery, rolling bottle go down to posterity cultivated for 2～3 generations after, peptic cell also prepares cell suspension;
Step 2: the multi-stage biological reaction vessel of human diploid cell strain is cultivated; The bioreactor Linear magnifying technology in high that the human diploid cell suspension that will after recovery, go down to posterity cultivation and digestion, process carries out more than the secondary is cultivated;
Step 3: inoculation encephalitis b virus strain, carry out virus multiplication and cultivate: the cell density in the final bioreactor that the bioreactor Linear magnifying technology in high is cultivated reaches 10
6After individual/ml is above, cell growth medium is replaced by virus keeps liquid, and the encephalitis b virus strain is seeded to wherein, carry out virus multiplication and cultivate;
Step 4: results virus-culturing fluid: change virus and keep liquid after 24 hours, the results virus-culturing fluid, simultaneously every day the sampling Detection virus-culturing fluid titre, every batch culture fluid results 15～25 days;
Step 5: the virus-culturing fluid of results is prepared vaccine after deactivation, ultrafiltration, purification and interpolation protective agent.
2. the production method of a kind of human diploid cell Inactivated Japanese Encephalitis Vaccine according to claim 1; It is characterized in that: described human diploid cell strain is WI-38, MRC-5,2BS; Among the KMB17 any, described encephalitis b virus strain are P3 strain or SA14-14-2 strain.
3. the production method of a kind of human diploid cell Inactivated Japanese Encephalitis Vaccine according to claim 1 is characterized in that: described bioreactor is that stirring type bioreactor or swing gas-liquid replace culture bioreactors.
4. the production method of a kind of human diploid cell Inactivated Japanese Encephalitis Vaccine according to claim 1 is characterized in that: said virus is kept liquid and is kept liquid for BME virus, and said protective agent is the glycoprotein protective agent.
5. the production method of a kind of human diploid cell Inactivated Japanese Encephalitis Vaccine according to claim 1 is characterized in that: the human diploid cell strain in the bioreactor of each of said step 2 grade reaches 10
6Behind the cell density more than individual/ml, digestion, eluting, centrifugation is collected and re-suspended cell, and is seeded to the next stage bioreactor culture according to magnification ratio through airtight pipe-line system.
6. the production method of a kind of human diploid cell Inactivated Japanese Encephalitis Vaccine according to claim 5; It is characterized in that: add microcarrier and the cell suspension that supplies cell to attach in each of said step 2 grade bioreactor, the concentration of cell suspension that adds in the said one-level bioreactor is 10
6Individual/more than the ml, the about 10L of the working volume of said one-level bioreactor culture, described magnification ratio are 10～20 times of previous stage bioreactor working volume.
7. the production method of a kind of human diploid cell Inactivated Japanese Encephalitis Vaccine according to claim 6 is characterized in that: the microcarrier that adds in described each grade bioreactor is that graininess solid microsphere carrier, porous are microsphere supported, in reticular fiber structure carrier and the sheet-like fiber structure carrier any.
8. the production method of a kind of human diploid cell Inactivated Japanese Encephalitis Vaccine according to claim 1 is characterized in that: the mode of said step 4 results virus-culturing fluid is compartment results culture fluid or continous pouring formula results culture fluid.
9. according to the production method of claim 4 or 8 described a kind of human diploid cell Inactivated Japanese Encephalitis Vaccine; It is characterized in that: described compartment results culture fluid is specially: behind the virus-culturing fluid of 24～48 hours results volume of culture 80%～90%, continue to add BME and keep liquid to former volume of culture at interval.
10. according to the production method of claim 4 or 8 described a kind of human diploid cell Inactivated Japanese Encephalitis Vaccine; It is characterized in that: described continous pouring formula results culture fluid is specially: flow out virus-culturing fluid every day continuously; And every day harvesting work volume 80%～90% virus-culturing fluid, equivalent is added BME and is kept liquid continuously simultaneously.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103591461A CN102406927A (en) | 2011-11-14 | 2011-11-14 | Method for producing human diploid cell encephalitis B inactivated vaccine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103591461A CN102406927A (en) | 2011-11-14 | 2011-11-14 | Method for producing human diploid cell encephalitis B inactivated vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102406927A true CN102406927A (en) | 2012-04-11 |
Family
ID=45909462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103591461A Pending CN102406927A (en) | 2011-11-14 | 2011-11-14 | Method for producing human diploid cell encephalitis B inactivated vaccine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102406927A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105695424A (en) * | 2015-04-01 | 2016-06-22 | 中国食品药品检定研究院 | Adaptive strain of Japanese encephalitis vaccine strain SA14-14-2 in human diploid cells 2BS and vaccine of adaptive strain |
| CN108384748A (en) * | 2018-03-14 | 2018-08-10 | 广州齐志生物工程设备有限公司 | A method of automation culture diploid cell |
| CN111235030A (en) * | 2020-03-10 | 2020-06-05 | 北京好思康科技有限公司 | System for producing viruses by two-stage mixed culture |
| CN112941036A (en) * | 2021-02-08 | 2021-06-11 | 吉林迈丰生物药业有限公司 | Method for improving replication level of rabies viruses in human diploid cells |
| CN114306587A (en) * | 2021-12-22 | 2022-04-12 | 辽宁成大生物股份有限公司 | Preparation method of low-serum Japanese encephalitis inactivated vaccine and Japanese encephalitis inactivated vaccine |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1586622A (en) * | 2004-08-13 | 2005-03-02 | 崔栋 | Diploid cell cerebritis B vaccine and purified cerebritis B vaccine, dosage form freeze-drying and water injection |
| CN101352569A (en) * | 2007-07-27 | 2009-01-28 | 崔栋 | Diploid somatic cell encephalitis B vaccine and method for preparing purified encephalitis B vaccine |
| CN102038943A (en) * | 2010-09-15 | 2011-05-04 | 武汉中博生物股份有限公司 | Method for industrially producing porcine Japanese encephalitis (JE) vaccines by utilizing bioreactor |
-
2011
- 2011-11-14 CN CN2011103591461A patent/CN102406927A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1586622A (en) * | 2004-08-13 | 2005-03-02 | 崔栋 | Diploid cell cerebritis B vaccine and purified cerebritis B vaccine, dosage form freeze-drying and water injection |
| CN101352569A (en) * | 2007-07-27 | 2009-01-28 | 崔栋 | Diploid somatic cell encephalitis B vaccine and method for preparing purified encephalitis B vaccine |
| CN102038943A (en) * | 2010-09-15 | 2011-05-04 | 武汉中博生物股份有限公司 | Method for industrially producing porcine Japanese encephalitis (JE) vaccines by utilizing bioreactor |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105695424A (en) * | 2015-04-01 | 2016-06-22 | 中国食品药品检定研究院 | Adaptive strain of Japanese encephalitis vaccine strain SA14-14-2 in human diploid cells 2BS and vaccine of adaptive strain |
| CN105695424B (en) * | 2015-04-01 | 2019-06-14 | 中国食品药品检定研究院 | Adapted strain and its vaccine of the Japanese Encephalitis Vaccine,Live strain SA14-14-2 on human diploid cell 2BS |
| CN108384748A (en) * | 2018-03-14 | 2018-08-10 | 广州齐志生物工程设备有限公司 | A method of automation culture diploid cell |
| CN111235030A (en) * | 2020-03-10 | 2020-06-05 | 北京好思康科技有限公司 | System for producing viruses by two-stage mixed culture |
| CN112941036A (en) * | 2021-02-08 | 2021-06-11 | 吉林迈丰生物药业有限公司 | Method for improving replication level of rabies viruses in human diploid cells |
| CN114306587A (en) * | 2021-12-22 | 2022-04-12 | 辽宁成大生物股份有限公司 | Preparation method of low-serum Japanese encephalitis inactivated vaccine and Japanese encephalitis inactivated vaccine |
| CN114306587B (en) * | 2021-12-22 | 2023-12-29 | 辽宁成大生物股份有限公司 | Preparation method of low-serum Japanese encephalitis inactivated vaccine and Japanese encephalitis inactivated vaccine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102816732B (en) | MDCK cell line suitable for full suspended serum-free culture and its application in culturing of influenza virus and production of influenza virus vaccines | |
| CN102000326B (en) | Method for producing rabies vaccine for human | |
| CN102406927A (en) | Method for producing human diploid cell encephalitis B inactivated vaccine | |
| CN114317405B (en) | Serum-free full-suspension culture type F81 cell line and construction method and application thereof | |
| CN103394081B (en) | WAVE wave bioreactor is utilized to produce the method for avian influenza vaccine | |
| CN103773741B (en) | The method that cage air agitation bioreactor prepares influenza vaccines | |
| CN111925982A (en) | Human bone marrow mesenchymal stem cell culture process applying three-dimensional cells | |
| CN102690790A (en) | Suspension culture production method for porcine circovirus 2-type cells | |
| CN107460154A (en) | Method for cultivating attached cell | |
| CN108179137B (en) | Preparation method of recombinant adeno-associated virus of serum 8 type | |
| CN102807964A (en) | Method for scale-up culture of animal cells | |
| CN104232564A (en) | Culture medium suitable for preparing hog cholera vaccines from ST cell and using method thereof | |
| CN103520715B (en) | Method for producing porcine circovirus II type inactivated vaccine by utilizing WAVE bioreactor | |
| CN104178459A (en) | Method of serum-free suspension culture of rabies virus | |
| CN108587914B (en) | Method for separating and purifying haematococcus pluvialis strain | |
| US9932562B2 (en) | Drain down and re-feed of microcarrier bioreactor | |
| CN107794248A (en) | A kind of method with microcarrier suspension culture CDV | |
| CN102038943A (en) | Method for industrially producing porcine Japanese encephalitis (JE) vaccines by utilizing bioreactor | |
| CN102038945A (en) | Method for industrially producing swine parvovirus vaccine by utilizing bioreactor | |
| Lawal et al. | Propagation and molecular characterization of bioreactor adapted very virulent infectious bursal disease virus isolates of Malaysia | |
| Hou et al. | A novel sequence batch membrane carbonation photobioreactor developed for microalgae cultivation | |
| WO2020083071A1 (en) | Microalgae purification culture medium and method for separation and purification of microalgae | |
| CN103614344A (en) | Method for amplifying porcine circovirus type 2 by applying bioreactor and flaky vector | |
| CN109666653B (en) | Subculture method of rabies vaccine virus and preparation method of rabies vaccine | |
| RU2488631C1 (en) | CELL LINE OF CALF KIDNEY Bos taurus RBT (Rene Bos Taurus) FOR REPRODUCTION OF ANIMAL VIRUSES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120411 |